PARP Inhibitors for Cancer Therapy
(Sprache: Englisch)
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP in cancer therapy. The volume covers the history of the discovery of PARP (poly ADP ribose polymerase) and its role in DNA repair. In addition, a description of...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
160.49 €
80 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „PARP Inhibitors for Cancer Therapy “
Klappentext zu „PARP Inhibitors for Cancer Therapy “
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP in cancer therapy. The volume covers the history of the discovery of PARP (poly ADP ribose polymerase) and its role in DNA repair. In addition, a description of discovery of the PARP family, and other DNA maintenance-associated PARPs will also be discussed. The volume also features a section on accessible chemistry behind the development of inhibitors. PARP inhibitors are a group of pharmacological inhibitors that are a particularly good target for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA damaging agents used to treat cancer. Researchers have learned a tremendous amount about the biology of PARP and how tumour-specific defects in DNA repair can be exploited by PARPi. The ¿synthetic lethality¿ of PARPi is an exciting concept for cancer therapy and has led to a heightened activity in this area.
Inhaltsverzeichnis zu „PARP Inhibitors for Cancer Therapy “
Section 1: What PARP is and What it Does 1. History of the discovery of poly (ADP-ribose)
Takashi Sugimura and Sydney Shall
2. Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members
Eléa Héberlé, Jean-Christophe Amé, Giuditta Illuzzi, Françoise Dantzer, Valérie Schreiber
3. The role of PARPs in DNA Strand Break Repair
Stuart L. Rulten, Françoise Dantzer and Keith W. Caldecott
4. TIPs: Tankyrase Interacting Proteins
Susan Smith
5. PARP and Carcinogenesis
Junhui Wang, Akira Sato, Hiroaki Fujimori, Yoshio Miki, Mitsuko Masutani
6. Multitasking roles for poly(ADP-ribosyl)ation in aging and longevityAswin Mangerich and Alexander Bürkle
Section 2. NAD catalysis and the identification of inhibitors
7. Overview of PARP Inhibitor Design and Optimization
Dana Ferraris
8. Structure Based Design of PARP Inhibitors
Stacie S. Canan
Section 3. Chemo- and radiosensitisation in vitro and in vivo
9. Preclinical chemosensitization by PARP inhibitors
David R. Shalinsky, Cherrie K. Donawho. Gerrit Los, and Joanne P. Palma
10. Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating
... mehr
agents
Junko Murai and Yves Pommier
11. Radiosensitisation by poly(ADP-ribose) polymerase inhibition
Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra, Vincent Favaudon, Vincent Pennaneach, Janet Hall
12. The vasoactivity of PARP inhibitors
Cian M. McCrudden and Kaye J. Williams
Section 4. Synthetic lethality
13. Synthetic lethality with Homologous Recombination Repair defects
Helen E. Bryant, Sydney Shall
14. Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality
Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow and Ester M. Hammond
15. Other determinants of sensitivity
Naoyuki Okita and Atsushi Shibata
16. Synthetic sickness with molecularly targeted agents against the EGFR pathway
Jennifer A. Stanley and Eddy S Yang
17. Disruption of DNA repair by cell cycle and transcriptional CDK inhibition
Liam Cornell, Neil Johnson and Geoffrey I. Shapiro
18. Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations
Kiranjit K. Dhillon and Toshiyasu Taniguchi
19. PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration
Guotai Xu, Jos Jonkers, Sven Rottenberg
Section 5. Clinical status
20. Introduction to PARPi clinical trials and future directions
Ruth Plummer and Yvette Drew
21. Clinical trials investigating PARP inhibitors as single agents
Sheeba Irshad and Andrew Tutt
22. Clinical trials of PARP inhibitors with chemotherapy
Ashley K. Clift, Nicholas Coupe and Mark R. Middleton
23. Combination of PARP inhibitors with clinical radiotherapy
Ross Carruthers, Anthony J. Chalmers
24. Biomarkers for PARP Inhibitors
C. Dearman, Ricky A. Sharma, Nicola Curtin
Junko Murai and Yves Pommier
11. Radiosensitisation by poly(ADP-ribose) polymerase inhibition
Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra, Vincent Favaudon, Vincent Pennaneach, Janet Hall
12. The vasoactivity of PARP inhibitors
Cian M. McCrudden and Kaye J. Williams
Section 4. Synthetic lethality
13. Synthetic lethality with Homologous Recombination Repair defects
Helen E. Bryant, Sydney Shall
14. Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality
Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow and Ester M. Hammond
15. Other determinants of sensitivity
Naoyuki Okita and Atsushi Shibata
16. Synthetic sickness with molecularly targeted agents against the EGFR pathway
Jennifer A. Stanley and Eddy S Yang
17. Disruption of DNA repair by cell cycle and transcriptional CDK inhibition
Liam Cornell, Neil Johnson and Geoffrey I. Shapiro
18. Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations
Kiranjit K. Dhillon and Toshiyasu Taniguchi
19. PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration
Guotai Xu, Jos Jonkers, Sven Rottenberg
Section 5. Clinical status
20. Introduction to PARPi clinical trials and future directions
Ruth Plummer and Yvette Drew
21. Clinical trials investigating PARP inhibitors as single agents
Sheeba Irshad and Andrew Tutt
22. Clinical trials of PARP inhibitors with chemotherapy
Ashley K. Clift, Nicholas Coupe and Mark R. Middleton
23. Combination of PARP inhibitors with clinical radiotherapy
Ross Carruthers, Anthony J. Chalmers
24. Biomarkers for PARP Inhibitors
C. Dearman, Ricky A. Sharma, Nicola Curtin
... weniger
Autoren-Porträt
Nicola Jane Curtin, Ph.D. is Professor of Experimental Cancer Therapeutics at Newcastle University. Dr. Curtin is also the team leader for DNA damage signalling and repair projects within CR-UK Drug Development Programme.Ricky Sharma is Associate Professor at the University of Oxford and Honorary Consultant in Clinical Oncology at the Oxford University Hospitals NHS Trust. He graduated in medicine from the University of Cambridge, and subsequently trained in toxicology, general internal medicine, medical oncology and clinical oncology in Cambridge, Glasgow, Leicester and London. Since 2006, he has led a translational research group at the University of Oxford focussed on DNA damage repair and the development of new chemotherapy and radiotherapy treatments for cancer.
Bibliographische Angaben
- 2015, 2015, XIX, 591 Seiten, 85 farbige Abbildungen, Maße: 16 x 24,1 cm, Gebunden, Englisch
- Herausgegeben: Nicola J. Curtin, Ricky A. Sharma
- Verlag: Springer, Berlin
- ISBN-10: 3319141503
- ISBN-13: 9783319141503
Sprache:
Englisch
Kommentar zu "PARP Inhibitors for Cancer Therapy"
0 Gebrauchte Artikel zu „PARP Inhibitors for Cancer Therapy“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "PARP Inhibitors for Cancer Therapy".
Kommentar verfassen